PharmTech Poll Results: OTC Children’s Medications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll Results: OTC Children’s Medications


Untitled Document

PharmTech Poll Results: OTC Children’s Medications

The question:

The US Food and Drug Administration’s Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee recently recommended that over-the-counter cough and cold medications not be given to children under age 6 based on their conclusion that the drugs have not been proven effective according to current research and there is a risk of adverse effects. The committees further recommended that dosing devices be required and standardized using volume measurements for liquid formulations.

Do you agree with the committees that there should be standardized dosing devices for all OTC children’s medications?

Your Answers:

Thanks to all of you who participated in our poll! All respondants agreed that OTC children’s medications should have standardized dosing devices.

One person commented, “These should be sold directly by the pharmacist like the pseudoephedrine formulations so the parents administering the doses understand how to use the dosing device and to make sure the patient is not taking other medication that could impact the dosing.”

To add your comments, click here.

For more on this topic, see:

Wyeth Recalls Cold Medicines, Lawmakers Urge FDA Action

FDA Committees Recommend Ban on Cough and Cold Medications for Young Children

Drug Makers Voluntarily Recall OTC Infant Cough and Cold Medications

FDA to Discuss Pediatric OTC Drugs, Warns Against Codeine Use

To see the results of our previous polls, see the poll archive.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced

Click here